Triflupromazine
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Triflupromazine
|
|
| Systematic (IUPAC) name | |
| N,N-dimethyl-3-[2-(trifluoromethyl)- 10H-phenothiazin-10-yl]-propan-1-amine | |
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C18H19F3N2S |
| Mol. mass | 352.418 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Triflupromazine is an antipsychotic medication of the phenothiazine class (brandname Vesprin). Among different effects of triflupromazine indication for use of this drug is severe emesis. Due to its potential side effects (triflupromazine has higher risk for side effects than many other antipsychotics) it is not gold standard in antiemetic therapy.
Serious side effects of trifluproamzine can be akathisia and tardive dyskinesia as well as the rare, but potentially fatal, neuroleptic malignant syndrome.
 |
This medical article is a stub. You can help Wikipedia by expanding it. |
